The effect of the doxycycline-rifampicin and levamisole combination on lymphocyte subgroups and functions of phagocytic cells in patients with chronic brucellosis.
BACKGROUND
Brucellosis is one of the important health problems for both humans and animals in Turkey since agriculture and stock raising appears to be the most important means of subsistence. Investigations on the pathogenesis of brucellosis reveal that the etiologic agent can survive in phagocytic cells, and cell-mediated immunity plays an important role in immunity against bacteria.


METHODS
In this study, we investigated whether supplementation of levamisole, a well-known antihelminthic agent with immune-stimulating activity to conventional antibiotic therapy, would improve the anergy against Brucella.


RESULTS
The results of our study reveal that a 6-week course of levamisole as a supplement to conventional antibiotic therapy in chronic brucellosis is not superior to conventional antibiotic treatment alone with respect to lymphocyte subgroup ratios and phagocytic function.


CONCLUSIONS
In chronic brucellosis, levamisole administered as a supplement concomitantly with conventional antibiotic therapy has no immunostimulating effect on the basis of the lymphocyte subgroups ratios measured and the ability of phagocytosis in the present study. Further large clinical and laboratory trials are necessary to investigate the immunological and physiological effects of levamisole on T(H1) subtypes and cytokine secretion.
Dizer
Ufuk
U
Department of Infectious Diseases and Clinical Microbiology, Gulhane Military Medical Academy, Ankara, Turkey. ufukdizer@hotmail.com
Hayat
Levent
L
Beker
Can Murat
CM
Görenek
Levent
L
Ozgüven
Volkan
V
Pahsa
Alaaddin
A
D017347:Brucella melitensis / Q000472:pathogenicity; D002006:Brucellosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004318:Doxycycline / Q000494:pharmacology*; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007978:Levamisole / Q000494:pharmacology*; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects*; D008297:Male; D010587:Phagocytosis / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology*; D014421:Turkey
D007978:Levamisole; D004318:Doxycycline; D012293:Rifampin